Engineering multi-specific nano-antibodies for cancer immunotherapy
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
In vitro
应用场景：
创建时间：
2023-10-21
相关数据集
Chapter 6- Deep Immunoprofiling HBV PD1/PD-L1
Correlation analysis is partially displayed in chapter 6 of thesis. Includes Spearmans R, 95% CI and P-values
DataCite Commons2022-07-18 更新70
Table_4_The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.xlsx
Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation propert
NIAID Data Ecosystem60
PEGylated graphene oxide-mediated stimulation of vascular endothelial cells and responsive release of PD-1/PD-L1 inhibitor for efficient chemo-immunotherapy against cancer
Immune checkpoint blockade (ICB) has emerged as a promising immunotherapeutic modality against cancer in the clinic. However, only 10–30% of patients respond to ICB, primarily due to poor immunogenici
科学数据银行2024-10-10 更新30
CD137 costimulation counteracts TGFβ inhibition of NK cell anti-tumor function and promotes the acquisition of tissue-resident Th9-like properties [4 treatments]. CD137 costimulation counteracts TGFβ inhibition of NK cell anti-tumor function and promotes the acquisition of tissue-resident Th9-like properties [4 treatments]
Enhancing NK cell-based cancer immunotherapy by overcoming immunosuppression is an unmet goal. Here, we demonstrate the ability of the anti-CD137 agonist urelumab for overcoming TGF-β-mediated inhibit
NIAID Data Ecosystem60
TMEscore and grouping information of samples used for subsequent analysis.
(XLSX)
NIAID Data Ecosystem50
